- Популярные видео
- Авто
- Видео-блоги
- ДТП, аварии
- Для маленьких
- Еда, напитки
- Животные
- Закон и право
- Знаменитости
- Игры
- Искусство
- Комедии
- Красота, мода
- Кулинария, рецепты
- Люди
- Мото
- Музыка
- Мультфильмы
- Наука, технологии
- Новости
- Образование
- Политика
- Праздники
- Приколы
- Природа
- Происшествия
- Путешествия
- Развлечения
- Ржач
- Семья
- Сериалы
- Спорт
- Стиль жизни
- ТВ передачи
- Танцы
- Технологии
- Товары
- Ужасы
- Фильмы
- Шоу-бизнес
- Юмор
The Backroom Deal To Shutdown Compound GLP-1 Access?
Millions of Americans lost access to affordable GLP-1 medications. Here's the backroom deal that made it happen — and who paid for it.
The active ingredient in Ozempic costs less than $5 to make a month's supply. Compounding pharmacies were selling it for $150–$300. Then the FDA shut it down — right as Eli Lilly and Novo Nordisk were cutting deals with the White House for tariff exemptions, expedited FDA approvals, and a contractual guarantee against future pricing mandates.
In this video: the seven-layer regulatory crackdown that killed the compounding market, the pipeline drugs both companies needed FDA approval for, the broader pattern (law firms, CBS/Paramount, Jeff Bezos), who loses coverage (19 million people, premiums up 114%), and the gray market the crackdown created — Chinese powder with 7% purity, fake Ozempic in legitimate pharmacies, a Utah doctor indicted for injecting 200+ patients with smuggled peptides.
This isn't a story about whether GLP-1s work. It's about who gets to access them — and who decided affordability is "not a clinical need."
⚠️ PUBLIC COMMENT DEADLINE — June 29, 2026: regulations.gov, docket 2026-08552
SOURCES: fda.gov | federalregister.gov | whitehouse.gov | cbo.gov | kff.org | cbp.gov | who.int | nclnet.org | safemedicines.org | Senate Finance Committee "Trump's Big Pharma Giveaway" report | Pharmacy Times | BioPharma Dive | Hollywood Reporter | Bloomberg Law
00:00 — Introduction: The $5 drug the government made illegal
01:02 — What are GLP-1s and why do they matter?
04:32 — The seven-layer regulatory squeeze
10:39 — The casualties: companies shut down
12:38 — The deal: follow the money
18:50 — The pattern: law firms, CBS, Bezos, and Big Pharma
24:10 — The human cost: 19 million losing coverage
27:40 — The gray market: what the crackdown actually created
32:22 — Closing: connect the dots
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: https://www.joinfridays.com/?via=RMZ
Gruns: https://grns.sjv.io/AgoLV7
========================================================
Social Links
https://www.tiktok.com/@roundmoundofzepbound
https://www.instagram.com/roundmoundofzepbound/
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
Видео The Backroom Deal To Shutdown Compound GLP-1 Access? канала Round Mound of Zepbound
The active ingredient in Ozempic costs less than $5 to make a month's supply. Compounding pharmacies were selling it for $150–$300. Then the FDA shut it down — right as Eli Lilly and Novo Nordisk were cutting deals with the White House for tariff exemptions, expedited FDA approvals, and a contractual guarantee against future pricing mandates.
In this video: the seven-layer regulatory crackdown that killed the compounding market, the pipeline drugs both companies needed FDA approval for, the broader pattern (law firms, CBS/Paramount, Jeff Bezos), who loses coverage (19 million people, premiums up 114%), and the gray market the crackdown created — Chinese powder with 7% purity, fake Ozempic in legitimate pharmacies, a Utah doctor indicted for injecting 200+ patients with smuggled peptides.
This isn't a story about whether GLP-1s work. It's about who gets to access them — and who decided affordability is "not a clinical need."
⚠️ PUBLIC COMMENT DEADLINE — June 29, 2026: regulations.gov, docket 2026-08552
SOURCES: fda.gov | federalregister.gov | whitehouse.gov | cbo.gov | kff.org | cbp.gov | who.int | nclnet.org | safemedicines.org | Senate Finance Committee "Trump's Big Pharma Giveaway" report | Pharmacy Times | BioPharma Dive | Hollywood Reporter | Bloomberg Law
00:00 — Introduction: The $5 drug the government made illegal
01:02 — What are GLP-1s and why do they matter?
04:32 — The seven-layer regulatory squeeze
10:39 — The casualties: companies shut down
12:38 — The deal: follow the money
18:50 — The pattern: law firms, CBS, Bezos, and Big Pharma
24:10 — The human cost: 19 million losing coverage
27:40 — The gray market: what the crackdown actually created
32:22 — Closing: connect the dots
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: https://www.joinfridays.com/?via=RMZ
Gruns: https://grns.sjv.io/AgoLV7
========================================================
Social Links
https://www.tiktok.com/@roundmoundofzepbound
https://www.instagram.com/roundmoundofzepbound/
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
Видео The Backroom Deal To Shutdown Compound GLP-1 Access? канала Round Mound of Zepbound
Комментарии отсутствуют
Информация о видео
21 ч. 12 мин. назад
00:35:25
Другие видео канала





















